Compare Eli Lilly And Co (LLY) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Visa Inc — how do they compare? Eli Lilly And Co trades at $1,173.56 (market cap $1.04T), while Visa Inc trades at $385.09 (market cap $704.20B). The key difference: Eli Lilly And Co is the larger of the two by market cap, and Visa Inc pays the higher dividend (0.71%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Visa Inc for 115 Days on average.
| LLY | V | |
|---|---|---|
Market Cap | $1.04T | $704.20B |
Volume | 3,064,878 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $1.28K | $384.14 |
52-Week Low | $799.57 | $295.52 |
Typical Hold Time | 93 Days | 115 Days |
Enterprise Value | $1.09T | $714.78B |
Dividend Yield | 0.59% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Visa (V) trades at $383.79, up 3.14% today, showing strong momentum near its 52-week high. The stock maintains bullish technical signals with consistent earnings beats and robust fundamentals, including 50.78% net margins and 61.79% ROE. Recent developments include AI-powered commerce initiatives and stablecoin partnerships, positioning Visa at the forefront of payment innovation while maintaining dominant market positioning.
Visa presents a compelling investment case with strong analyst support (85% buy ratings) and a $422.24 price target offering 10% upside. However, elevated valuation multiples (P/E 31.92) and emerging fintech competition require monitoring. The company's consistent execution and AI integration provide growth catalysts, though regulatory scrutiny and payment disruption risks remain considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
